Satellos Bioscience Inc. | LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Satellos Bioscience (MSCL) announce Co-founder and Chief Scientific Officer Dr. Michael Rudnicki is awarded a seven-figure, five-year grant from the Canadian Institutes of Health Research (CIHR)
  • The grant is entitled “Muscle Stem Cell Function in Duchenne Muscular Dystrophy”
  • Satellos (MSCL) is a biotechnology company dedicated to developing lifechanging medicines to treat degenerative muscle conditions
  • Satellos (MSCL) is up 1.89 per cent on the day, trading at C$0.54 per share at 1:20 pm ET

Doctor Michael Rudnicki, Co-founder and Chief Scientific Officer of Satellos Bioscience (MSCL) received a five-year grant from the Canadian Institutes of Health Research (CIHR).

The grant entitled “Muscle Stem Cell Function in Duchenne Muscular Dystrophy” was awarded by the Genetics Research Panel. The $1,071,000 grant will support the research led by Dr. Rudnicki at the Ottawa Hospital Research Institute to investigate the molecular pathobiology in muscle stem cells that contributes to disease progression in Duchenne muscular dystrophy.

Dr. Rudnicki made the paradigm-shifting discovery that loss of polarity control in muscle stem cells is a significant driver of disease in Duchenne, resulting in his appointment to the Royal Society. Extending these studies is the subject of the research supported by this new grant from the Canadian Institutes of Health Research. Dr. Rudnicki’s discovery also underpins the drug development efforts underway at Satellos Bioscience. Targeting polarity control in stem cells to enhance regeneration as a treatment for Duchenne and other muscle disorders.

Frank Gleeson, CEO and Co-Founder of Satellos says:

“Deemed the number one ranked genetics panel proposal, this award further exemplifies the scientific community’s excitement and strong support for pursuing the understanding of stem cell function in Duchenn. We’re proud to have Michael as a central part of the Satellos team, and excited to celebrate the high profile and deserved accolades he and his work continue to receive.”

Along with his role as Co-founder and CSO with Satellos, Dr. Rudnicki is a Senior Scientist and Director of the Regenerative Medicine Program and the Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute – the research arm of The Ottawa Hospital. The Canadian Institutes of Health Research is Canada’s federal funding agency for health research. Composed of 13 Institutes, CIHR collaborates with partners and researchers to support discoveries and innovations that improve health and strengthen the Canadian health care system.

Satellos (MSCL) is a biotechnology company dedicated to developing lifechanging medicines to treat degenerative muscle conditions.

Satellos (MSCL) is up 1.89 per cent on the day, trading at C$0.54 per share at 1:20 pm ET.


.

More From The Market Herald

" MCI Onehealth (TSX:DRDR) and Euclid Telehealth work to improve patient vision

MCI Onehealth (DRDR) and Euclid Telehealth are collaborating to increase access to care that can potentially prevent vision loss among Ontario patients.

" Spectral Medical (TSX:EDT) reports Q2 2022 results

Spectral Medical (EDT) released its financial results for the second quarter ended June 30, 2022.

" Hemostemix (TSXV:HEM) closes second tranche of non-brokered private placement

Hemostemix (HEM) has closed the second tranche of a non-brokered private placement of units for gross proceeds of $1,364,710.10.

" Nova Leap Health (TSXV:NLH) posts 2nd highest Q2 results in its history

Nova Leap Health (NLH) released its financial results for the quarter ended June 30, 2022.